NET CONNECT has summarised highlights of the recent ESMO 2019 meeting for you. Neuroendocrine Tumour Update by Dr Angela Lamarca, The Christie NHS Foundation Trust / University of Manchester, UK
NET CONNECT has summarised highlights of the recent ESMO 2019 meeting for you. Neuroendocrine Tumour Update by Dr Angela Lamarca, The Christie NHS Foundation Trust / University of Manchester, UK
Dr Angela Lamarca is a Medical Oncologist (MD, PhD, MSc), specialised in gastrointestinal malignancies (hepato-pancreato-biliary (HPB) and neuroendocrine tumours (NETs)). She completed her training in Medical Oncology (including her PhD) in Spain (Hospital Universitario La Paz, Madrid). She moved to The Christie NHS Foundation Trust (Manchester, United Kingdom) in 2013, where she completed a 4-year fellowship programme in HPB and NETs; during this period she received funding from ESMO (European Society for Medical Oncology) Translational Fellowship Programme, Pancreatic Cancer Research Fund and The Spanish Society of Medical Oncology (SEOM) Fellowship Grant Programme. Dr Lamarca has completed a Masters Degree in Molecular Biology of Cancer and a second Masters Degree in Biostatistics. She was awarded with an American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award in 2017 and was appointed as a Consultant in Medical Oncology at The Christie NHS Foundation Trust in May 2017 where she continues her Clinical and Translational Research career in HPB and NETs. She is actively involved in clinical trial design with special interest in NETs and HPB, focused on achieving a better understanding of these malignancies and identification of new therapies for improving patients’ outcome. Dr Angela Lamarca is a member of the EORTC Gastrointestinal Cancer Group and a faculty member of the ESMO Neuroendocrine, Endocrine Neoplasms and CUP Group.
AAA, Bayer, EISAI, Merck, Mylan and Delcath, Novartis, Nutricia, Roche, SrtEx and QED.
Using molecular testing to enable personalised care
Optimising diagnostic pathways
Experts discuss 2nd line+ treatment strategies in endocrine therapy-eligible patients
Expert insights on the latest data
Understanding EP-NEC, emerging treatments, and patient care strategies
Strategies to optimise the treatment experience